Enhanced in vivo immunogenicity of SIV vaccine candidates with cationic liposome-DNA complexes in a rhesus macaque pilot study.
This pilot study tested the immunogenicity of a novel cationic liposome-DNA complex (CLDC) immunomodulatory vaccine adjuvant. Combined with a specific antigen, CLDC enhanced anti-SIV immune responses induced by various SIV vaccine candidates. Rhesus macaques immunized in the presence of CLDC developed stronger SIV-specific T and B cell responses compared to animals immunized without CLDC. These differences persisted and resulted in better memory responses after an in vivo boost of the animals several months later with whole AT-2 inactivated SIVmac239. Thus, CLDC should be explored further as a potential immunomodulatory adjuvant in HIV vaccine design.
Fairman
Jeff
J
Juvaris BioTherapeutics, Inc., Burlingame, CA, USA.
Moore
Joseph
J
Lemieux
Mathieu
M
Van Rompay
Koen
K
Geng
Yongzhi
Y
Warner
John
J
Abel
Kristina
K
D000276:Adjuvants, Immunologic / Q000008:administration & dosage*; D000818:Animals; D001402:B-Lymphocytes / Q000276:immunology; D007156:Immunologic Memory; D008081:Liposomes / Q000008:administration & dosage*; D008253:Macaca mulatta; D008297:Male; D009838:Oligodeoxyribonucleotides / Q000008:administration & dosage*; D010865:Pilot Projects; D018449:SAIDS Vaccines / Q000276:immunology*; D016097:Simian Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D013601:T-Lymphocytes / Q000276:immunology
D000276:Adjuvants, Immunologic; C408982:CPG-oligonucleotide; D008081:Liposomes; D009838:Oligodeoxyribonucleotides; D018449:SAIDS Vaccines